Cexacoline is a novel drug that primarily acts as a selective agonist for the alpha7 nicotinic acetylcholine receptor (nAChR). It has been investigated for its potential therapeutic effects in cognitive disorders, particularly in conditions like schizophrenia and Alzheimer's disease. By enhancing cholinergic signaling, cexacoline aims to improve cognitive function and memory. Its development is part of ongoing research into targeted treatments for neurodegenerative and psychiatric conditions.